The Oxford vaccine for Covid-19 use has been given the go-ahead. The UK now has two authorised vaccines to help fight the pandemic.
In very good news for the whole of the UK, yhe Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s Covid-19 vaccine for use. This follows rigorous clinical trials and a thorough analysis of the data by experts at the MHRA, which has concluded that the vaccine has met its strict standards of safety, quality and effectiveness.
The Joint Committee on Vaccination and Immunisation (JCVI) will also publish its latest advice for the priority groups to receive this vaccine.
The roll-out of the Pfizer/BioNTech vaccine will continue, but the NHS will begin rolling out the Oxford University/AstraZeneca vaccine next week.
Having studied evidence on both the Pfizer/BioNTech and Oxford University/AstraZeneca vaccines, the JCVI has advised the priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.
Everyone will still receive their second dose and this will be within 12 weeks of their first, a much greater gap than was previously announced. The second dose completes the course and is important for longer term protection.
Pascal Soriot, Chief Executive Officer, said: "Today is an important day for millions of people in the UK who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit. We would like to thank our many colleagues at AstraZeneca, Oxford University, the UK government and the tens of thousands of clinical trial participants."
Matt Hancock, UK Secretary of State for Health and Social Care, said: "This is a moment to celebrate British innovation - not only are we responsible for discovering the first treatment to reduce mortality for Covid-19, this vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease. It is a tribute to the incredible UK scientists at Oxford University and AstraZeneca whose breakthrough will help to save lives around the world. I want to thank every single person who has been part of this British success story. While it is a time to be hopeful, it is so vital everyone continues to play their part to drive down infections."
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: "The regulator's assessment that this is a safe and effective vaccine is a landmark moment, and an endorsement of the huge effort from a devoted international team of researchers and our dedicated trial participants. Though this is just the beginning, we will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere, as many as possible as soon possible."
.
The thriving world of deals is the backbone of the Thames Valley’s property sector. Ensuring…
Malmesbury-based Dyson has unveiled a sophisticated wet floor cleaner for hard floor surfaces. It will…
Paris Smith LLP has been named the ‘Large Firm of the Year’ at the Hampshire…
Research* by Isio and YouGov, who surveyed over 7,000 private sector employees, has found that…
Buckinghamshire-based Starboard Hotels has announced the opening of Ibis Styles Gatwick following a £14 million…
Independent family brewer and pub company Shepherd Neame has been granted use of the royal warrant by…